The Crohn’s disease(CD) therapy market will continue to evolve over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite these agent’s limitations in efficacy (e.g., patients lose response over time) and safety risks. Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, and the introduction of the first-in-class interleukin (IL)-12/23 inhibitor, Janssen’s Stelara, have expanded physicians’ treatment armamentarium, especially for patients refractory to TNF-α inhibitors. Emerging therapies, which offer more-convenient formulations and/or havenovel mechanisms of action (e.g., Galapagos/Gilead’s filgotinib, TiGenix/Takeda’s Alofisel, AbbVie’s risankizumab), together with the increasing availability of biosimilar agents, will only intensify the competition.


  • What are key opinion leaders’ (KOLs’) insights on current treatment options (e.g., Remicade, Humira)? What is their perception of biosimilar agents? What factors drive their treatment decisions?
  • How have/will the newer, non-TNF biologics (e.g., Janssen’s Stelara, Takeda’s Entyvio, Roche’s etrolizumab) affect the CD treatment algorithm?
  • What do KOLs think about emerging oral therapies (e.g., Galapagos/Gilead’s filgotinib, AbbVie’s upadacitinib)? What impact will stem-cell therapy (i.e., TiGenix/Takeda’s Alofisel) have on the CD market?
  • How will the market evolve over the next ten years? What are KOLs’ insights on current treatment options for CD (e.g., Remicade, Humira, Inflectra/Remsima)? What factors drive their treatment decisions?


Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • September 2019
      • June 2019
      • November 2018
      • September 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Crohn's Disease?
        • What Factors Are Constraining the Market for Crohn's Disease?
      • Drug-Class-Specific Trends
        • TNF-Alpha Inhibitors
        • IL-12/IL-23 Inhibitors
        • CAM Inhibitors
        • IL-23 Inhibitors
        • JAK Inhibitors
        • Stem-Cell Therapies
        • S1P Receptor Modulators
        • Oral Aminosalicylates
        • Immunosuppressants
        • Corticosteroids
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology and Pathophysiology
        • Overview
        • Genetic Influence
        • Microbial Involvement
        • Environmental Factors
        • Mucosal Immune Response
        • Chronic Inflammation
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Crohn's Disease
        • Diagnosed Prevalent Cases of Crohn's Disease by Disease Activity
        • Diagnosed Cases of Crohn's Disease
        • Drug-Treated Cases of Crohn's Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • TNF-Alpha Inhibitors
        • CAM Inhibitors
        • IL-12/23 Inhibitors
        • Aminosalicylates
        • Immunosuppressants
        • Corticosteroids
        • Antibiotics
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Crohn's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Crohn's Disease
        • Interleukin-23 Inhibitors
        • Stem-Cell Therapies
        • CAM Inhibitors
        • JAK Inhibitors
        • Sphingosine-1-Phosphate Receptor Modulators
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Crohn's Disease
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Crohn's Disease Bibliography

Author(s): Ritesh Gupta, PhD; Qinghui Yu, PhD; Abey John, MPH

Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.

Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis (EU)

Multiple well-established therapies are available to treat Crohn’s disease (CD). In particular, the most widely used biologics—the

View Details

Crohn's Disease | Access & Reimbursement | Detailed, Expanded Analysis (US)

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (

View Details

Crohn's Disease | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK Treatment of moderate to severe Crohn’s disease (CD) typically begins with safe, albeit often less-efficacious,...

View Details

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Childr...

View Details